Peter Barton
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, HER2/EGFR in Cancer Research, Lung Cancer Treatments and Mutations, Epigenetics and DNA Methylation
Most-Cited Works
- → Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs(2020)221 cited
- → Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6(2018)136 cited
- → Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors(2017)78 cited
- → Identification, Optimization, and Pharmacology of Acylurea GHS-R1a Inverse Agonists(2014)35 cited
- → Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy(2017)33 cited
- → Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance(2021)31 cited
- → Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase(2021)28 cited
- → Identification of pyrazolo-pyrimidinones as GHS-R1a antagonists and inverse agonists for the treatment of obesity(2012)25 cited
- → Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs(2016)22 cited
- → Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase(2021)21 cited